CYYNF
Price
$0.15
Change
-$0.00 (-0.00%)
Updated
May 16 closing price
Capitalization
26.13M
URGN
Price
$4.24
Change
+$0.27 (+6.80%)
Updated
May 30 closing price
Capitalization
195.27M
79 days until earnings call
Interact to see
Advertisement

CYYNF vs URGN

Header iconCYYNF vs URGN Comparison
Open Charts CYYNF vs URGNBanner chart's image
Cynata Therapeutics
Price$0.15
Change-$0.00 (-0.00%)
Volume$666
Capitalization26.13M
UroGen Pharma
Price$4.24
Change+$0.27 (+6.80%)
Volume$2.9M
Capitalization195.27M
CYYNF vs URGN Comparison Chart
Loading...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYYNF vs. URGN commentary
Jun 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYYNF is a Hold and URGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 01, 2025
Stock price -- (CYYNF: $0.15 vs. URGN: $4.24)
Brand notoriety: CYYNF and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYYNF: 38% vs. URGN: 218%
Market capitalization -- CYYNF: $26.13M vs. URGN: $195.27M
CYYNF [@Biotechnology] is valued at $26.13M. URGN’s [@Biotechnology] market capitalization is $195.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $303.58B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYYNF’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • CYYNF’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, CYYNF is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

URGN’s TA Score shows that 4 TA indicator(s) are bullish.

  • URGN’s TA Score: 4 bullish, 6 bearish.

Price Growth

CYYNF (@Biotechnology) experienced а 0.00% price change this week, while URGN (@Biotechnology) price change was +1.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.39%. For the same industry, the average monthly price growth was +0.48%, and the average quarterly price growth was -5.03%.

Reported Earning Dates

URGN is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+1.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($195M) has a higher market cap than CYYNF($26.1M). CYYNF YTD gains are higher at: -21.053 vs. URGN (-60.188). CYYNF has higher annual earnings (EBITDA): -10.8M vs. URGN (-110.34M).
CYYNFURGNCYYNF / URGN
Capitalization26.1M195M13%
EBITDA-10.8M-110.34M10%
Gain YTD-21.053-60.18835%
P/E RatioN/AN/A-
RevenueN/A90.4M-
Total CashN/A237M-
Total DebtN/A123M-
FUNDAMENTALS RATINGS
CYYNF vs URGN: Fundamental Ratings
CYYNF
URGN
OUTLOOK RATING
1..100
5053
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
4798
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYYNF's Valuation (49) in the null industry is in the same range as URGN (74) in the Biotechnology industry. This means that CYYNF’s stock grew similarly to URGN’s over the last 12 months.

CYYNF's Profit vs Risk Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that CYYNF’s stock grew similarly to URGN’s over the last 12 months.

CYYNF's SMR Rating (95) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that CYYNF’s stock grew similarly to URGN’s over the last 12 months.

CYYNF's Price Growth Rating (47) in the null industry is somewhat better than the same rating for URGN (98) in the Biotechnology industry. This means that CYYNF’s stock grew somewhat faster than URGN’s over the last 12 months.

CYYNF's P/E Growth Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that CYYNF’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
URGN
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 24 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GIDUX7.940.03
+0.38%
Goldman Sachs Intl Eq Div & Prem R6
WGISX14.600.02
+0.14%
Wasatch International Select Instl
ERLVX25.810.02
+0.08%
Eaton Vance Large-Cap Value R6
FDTZX22.83N/A
N/A
Fidelity Advisor Capital Development M
MNNAX55.40-0.03
-0.05%
Victory Munder Multi-Cap A

CYYNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYYNF has been loosely correlated with CADL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CYYNF jumps, then CADL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYYNF
1D Price
Change %
CYYNF100%
N/A
CADL - CYYNF
46%
Loosely correlated
-6.84%
URGN - CYYNF
38%
Loosely correlated
+6.80%
MLLCF - CYYNF
31%
Poorly correlated
N/A
INKT - CYYNF
27%
Poorly correlated
+1.01%
BRTX - CYYNF
26%
Poorly correlated
+0.29%
More